Biotech Co.*
(Country;
Symbol)

Pharma Co.
(Country)

Product

Terms/Details (Date)


Affibody AB*
(Sweden)

Funakoshi Co. Ltd. (Japan)

Funakoshi will promote and distribute Affibody research reagents in Japan

Terms of the deal were not disclosed (10/4)

 

Alpha
Innotech Corp.*

GE Healthcare (UK)

Alpha Innotech will develop a line of imaging systems for GE

The products will be sold worldwide under the GE brand; terms of the deal were not disclosed (9/2)

 

Ambion Inc.*

GE Healthcare (UK)

GE will manufacture microRNA microarrays for Ambion

GE will use its CodeLink Bioarray technology in the license supply agreement; terms of the deal were not disclosed (9/29)

 

Auxilium
Pharmaceuticals
Inc.
(AUXL)

DPT Laboratories

They extended deal for the manufacturing of Testim through 2010

The deal for manufacturing Auxilium's Testim was set to expire in 2005; DPT will  manufacture it under undisclosed terms (9/21)

 

Cephalon Inc.(CEPH)

McNeil Consumer & Specialty Pharmaceuticals

Deal to co-promote Attenace (modafinil), for which an sNDA has been field with the FDA for treating attention deficit/ hyperactivity disorder

Cephalon will pay McNeil commission fees on sales of Attenace in the deal, which will last up to three years(9/1)

 

Codexis Inc.*

Arch Pharmalabs Ltd. (India)

Codexis will use its Molecular- Breeding technology to manufacture an undisclosed compound for Arch

Codexis is entitled to up-front and milestone payments from Arch, a generic pharmaceutical company (10/11)

 

Codexis Inc.*

Matrix Laboratories Ltd. (India)

Deal to develop a process for the manufacture of an undisclosed drug

Codexis is entitled to R&D funding, milestone payments and royalties; it will use its MolecularBreeding technology in the effort (10/11)

 

CombiMatrix
Group
(CBMX)
for CombiMatrix

VWR International Inc.

VWR will distribute Custom- Arrays and CatalogArrays

Terms of the global distribution agreement were not disclosed (9/13)

 

Cortex
Biochem Inc.*

Vita Inc. (Japan)

Vita will market Cortex products in Japan

The deal covers the MagaZorb Nucleic Acid Isolation Kits and associated reagents, and magnetic separation and immunoreagent products (10/11)

 

Enobia
Pharma Inc.*
(Canada)

Laureate Pharma Inc.

Deal for the process development and manufacture of  Enobia's recombinant enzyme sPHEX Metallo Peptidase

Phase I trials are expected to start in 3Q:06; terms of the deal were not disclosed (9/21)

 

ExonHit
Therapeutics
SA*
(France)

Agilent Technologies Inc.

Agilent will distribute ExonHit's SpliceArrays technology

SpliceArrays is a new generation of micro- arrays to detect alternative splicing (9/1)

 

Hemispherx
Biopharma
Inc.
(AMEX:HEB)

HollisterStier Laboratories

They signed a letter of intent for the contract manufacturing of Hemispherx's Ampligen

Terms of the deal were not disclosed (10/10)

 

IBEX
Technologies
Inc.
(Canada;
TSE:IBT)

Seikagaku Corp. (Japan) and Prozyme Inc.

Seikagaku and Prozyme will market IBEX enzymes to  customers in the worldwide  research community

Terms of the deal with Prozyme and Seikagaku subsidiary Associates of Cape Cod Inc. were not disclosed (9/20)

 

ImmunoGen
Inc.
(IMGN)

Diosynth Biotechnology (unit of NV Organon)

Diosynth will manufacture ImmunoGen's huN901 antibody

The antibody will be used in ImmunoGen's huN901-DM1 anticancer compound (10/6)

 

InSite Vision
Inc.
(AMEX:ISV)

Cardinal Health

Cardinal will manufacture commercial supplies of AzaSite (1% azithromycin)

Cardinal has been manufacturing the anti- infective for clinical trials; terms were not disclosed (9/22)

 

Mesoblast Ltd.
(Australia; ASX:MSB)

Cambrex Corp.

Deal for large-scale production of Mesoblast's adult stem cells

Cambrex will produce clinical-grade cells under undisclosed terms (9/20)

 

NeoPharm
Inc.
(NEOL)

Diosynth Biotechnology (unit of NV Organon)

They amended manufacturing deal covering NeoPharm's IL13-PE38QQR

Deal covers manufacturing following the  ongoing Phase III trial in brain cancer if NeoPharm moves ahead with BLA filing (9/21)

 

Peptech Ltd.
(Australia;
ASX:PEP)

Undisclosed
company

Deal for the manufacturing of Peptech's anti-TNF domain  antibody

The unnamed company will manufacture the antibody to GMP standards (9/12)

 

ProtoKinetix
Inc.
(OTC BB:PKTX)

Undisclosed company

Deal to study ProtoKinetix's AAGP for the stabilization of the partner's vaccines

AAGP is a synthetic antifreeze glycoprotein; terms of the deal were not disclosed (10/6)

 

Samaritan
Pharmaceuticals
Inc.
(AMEX:LIV)

Norbrook Laboratories S.R.O. (Northern Ireland)

Norbrook would supply raw formulation material to Samaritan's manufacturing partner upon approval of SP-01A

SP-01A is Samaritan's lead HIV drug; its manufacturing partner is Pharmaplaz (9/27)

 

Vernalis plc
(UK; LSE:VER)

Diosynth Biotechnology (unit of NV Organon) V10153 for Phase III trials

Deal for the process development, scale-up and manufacturing of Vernalis'

Diosynth will manufacture the thrombolytic agent under undisclosed terms (9/22)


Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

ASX = Australian Stock Exchange; AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.